Acute Graft-Versus-Host Disease
- PMID: 39437118
- Bookshelf ID: NBK608233
- DOI: 10.1007/978-3-031-44080-9_43
Acute Graft-Versus-Host Disease
Excerpt
Acute graft-versus-host disease (GvHD) remains a major course of short term (100 days and 1 yr) mortality and morbidity after allogeneic stem cell transplantation. The pathophysiology of GvHD is described as a 3 step process starting with initial tissue damage by conditioning followed by host antigen presenting cell activation by damage and pathogen associated molecular patterns and finally resulting in activation of alloreactive T cells and proinflmmatory cytokines inducing target cell apoptosis. This activating cycle elicits multiple regulatory mechanisms and cells such as regulatory T cells and myeloid derived suppressor cells. Besides the disturbed balance between immune activation and immune tolerance, a disturbed capacity of tissue repair contributes to clincal damage.
Copyright 2024, The Author(s).
Sections
References
-
- Cahn JY, Klein JP, Lee SJ, et al. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood. 2005;106:1495–500. - PMC - PubMed
-
- Chen YB, Shah NN, Renteria AS, Cutler C, Jansson J, Akbari M, Chen C, Quadri S, Parfionovas A, Devine SM. Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2019;3(23):4136–46. doi: 10.1182/bloodadvances.2019000893. PMID: 31821456; PMCID: PMC6963235. - PMC - PubMed
-
- Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945–56. - PubMed
-
- Finke J, Bethge WA, Schmoor C, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10:855–64. - PubMed
Publication types
LinkOut - more resources
Full Text Sources